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Brevia 
 
Aerosol borne varicella zoster virus (VZV) enters the nasopharynx and replicates in 
tonsillar T-cells, resulting in viremia and varicella (chickenpox).  Virus then becomes 
latent in cranial nerve, dorsal root and autonomic nervous system ganglia along the entire 
neuraxis (1).  Decades later, as cell-mediated immunity to VZV declines (4), latent VZV 
can reactivate to produce zoster (shingles).  Infectious VZV is present in patients with 
varicella or zoster, but shed of infectious virus in the absence of disease has not been 
shown.  We previously detected VZV DNA in saliva of astronauts during and shortly 
after spaceflight, suggesting stress induced subclinical virus reactivation (3).  We show 
here that VZV DNA as well as infectious virus in present in astronaut saliva. 
 
VZV DNA was detected in saliva during and after a 13-day spaceflight in 2 of 3 
astronauts (Fig. panel A).  Ten days before liftoff, there was a rise in serum anti-VZV 
antibody in subjects 1 and 2, consistent with virus reactivation.  In subject 3, VZV DNA 
was not detected in saliva, and there was no rise in anti-VZV antibody titer.  Subject 3 
may have been protected from virus reactivation by having zoster <10 years ago, which 
provides a boost in cell-medicated immunity to VZV (2).   No VZV DNA was detected in 
astronaut saliva months before spaceflight, or in saliva of 10 age/sex-matched healthy 
control subjects sampled on alternate days for 3 weeks (88 saliva samples). 
 
Saliva taken 2-6 days after landing from all 3 subjects was cultured on human fetal lung 
cells (Fig. panel B).  Infectious VZV was recovered from saliva of subjects 1 and 2 on the 
second day after landing.  Virus specificity was confirmed by antibody staining and DNA 
analysis which showed it to be VZV of European descent, common in the US (5).  
Further, both antibody staining and DNA PCR demonstrated that no HSV-1 was detected 
in any infected culture. 
 
This is the first report of infectious VZV shedding in the absence of clinical disease.  
Spaceflight presents a uniquely stressful environment which includes physical isolation 
and confinement, anxiety, sleep deprivation, as well as exposure to increased radiation 
and microgravity.  It is interesting that in our study, VZV and not HSV-1 reactivation 
was detected, since stress-induced HSV-1 reactivation has been reported (6).  Future 
studies are needed to determine the specific inducer of VZV reactivation. 
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Figure legend.  Subclinical shed of infectious VZV in astronaut saliva.  Panel A:  DNA 
was extracted from saliva samples collected 109-133 days before liftoff (preflight), days 
2-13 during flight (inflight, yellow area) and for 14 days after landing (post flight).  The 
VZV DNA copy number per ml saliva is shown in blue boxes.  VZV DNA was detected 
in 2 of 3 astronauts during and shortly after spaceflight.  A rise in titer of circulating anti-
VZV-specific antibody was also detected in the two subjects whose saliva was positive 
for VZV DNA.  Panel B:  Infectious virus was obtained from the saliva samples obtained 
on day 2 post flight from subjects 1 and 2, but not from subject 3.  Pictures in row 1 show 
VZV-specific staining in cells that had been inoculated with saliva of subjects one and 
two; no staining was seen in cells that had been inoculated with saliva of subject three.  
Row 2 is an enlargement of the stained monolayers showing multiple VZV-specific 
plaques (magnification bar = 2.0 mm).  Row 3 is a further enlargement showing a single 
VZV plaque (magnification bar = 0.2 mm).  Material and methods are presented in the 
accompanying supplemental data. 
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Supplemental data. 
 
Subjects.  All human study protocols were approved by the Committee for the Protection 
of Human Subjects of the Johnson Space Center, Houston, TX, and informed consent was 
obtained from all subjects. 
  
Saliva samples.  Saliva was collected with Salivette kits (Sarstedt, NC), concentrated by 
ultrafiltration, and DNA extracted by affinity chromatography on silica-matrix as 
previously described (5). 
 
Real-Time PCR.  TaqMan primers and probes for cellular GAPdH and VZV gene 63 
were used to determine virus genome copy number by fluorescence-based simultaneous 
amplification and product detection (5). 
 
Virus detection.  HFL cell cultures were inoculated with saliva samples and passed twice 
before fixation in 4% paraformaldehyde for immunostaining with rabbit anti-VZV-IE63 
or anti-HSV-1-ICP22 antibody (4). 
 
Plasma antibody testing.  The endpoint antibody titer to VZV was determined as the 
highest dilution of plasma giving positive immunofluorescent staining of VZV-infected 
cells. All specimens were batch analyzed and read blind-coded (6). 
 
VZV genotype analysis.  PCR-based diagnostic assays were performed on extracted 
DNA (2).  Single nucleotide polymorphisms in ORF38, ORF54 and ORF62 (positions 
106262 and 107252) were determined using fluorescent resonance energy transfer-based 
PCR performed on LightCycler (3).  Sequence variation within ORF21 (positions 33725-
33728) and ORF22 (positions 37837-38264) was determined to accurately identify virus 
genotype.  Nucleotide locations are based on the sequence of Dumas strain (1). 
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AME ns ns  1:80  1:80  1:80
Preflight -133 0 0 0
Preflight -131 0 0 0
Preflight -129 0 0 0
Preflight -127 0 0 0
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Inflight 1 ns ns ns
Inflight 2 224 18 0
Inflight 3 0 247 0
Inflight 4 0 0 0
Inflight 5 128 0 0
Inflight 6 0 0 0
Inflight 7 200 0 0
Inflight 8 0 0 0
Inflight 9 2500 650 0
Inflight 10 0 75 0
Inflight 11 450 0 0
Inflight 12 0 0 0
Inflight 13 120 23 0
postflight 14 ns ns ns  1:320  1:320  1:80
postflight 15 1250 560 0
postflight 16 45 0 0
postflight 17 0 340 0
postflight 18 110 45 0
postflight 19 0 23 0
postflight 20 0 0 0
postflight 21 0 0 0
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postflight 23 0 0 0
postflight 24 0 0 0
postflight 25 0 0 0
postflight 26 0 0 0
postflight 27 0 0 0  1:80  1:80  1:80
postflight 28 0 0 0
AME; annual medical exam (1-3 months prior to liftoff)
VZV antibody titerVZV copies / ml saliva
subject 1 subject 2 subject 3
A B
